What is the best anticoagulation regimen for the prevention of cardioembolism from AF in patients with a history of cancer?
A subgroup analysis in the ROCKET AF trial comparing rivaroxaban and warfarin in patients with AF and history of cancer showed similar rates of stroke and systemic embolism (0.52 (95% CI, 0.22 1.21)) and nonmajor bleeding (0.37 (95% CI, 0.17 0.79]) compared with warfarin. Similarly, DOACs showed a trend for more efficacy and better safety compared with warfarin in patients with AF and cancer in the ARISTOTLE trial. This was supported by claims data analysis looking at bleeding events of rivaroxaban.